Skip to Main Content

Paper Details

Venetoclax-based Rational Combinations are Effective in Models of <i>MYCN</i>-amplified Neuroblastoma.
Mol Cancer Ther
9
2021
BCL-2, BCL-2-dependent hematologic cancers, BH3-only protein NOXA, MCL, MCL-1, MDM2, MYCN, MYCN-amplified Neuroblastoma, MYCN-amplified neuroblastoma, MYCN-amplified neuroblastoma models, MYCN-amplified patient-derived xenograft models, NVP-CGM097, Neuroblastoma, S63845, Venetoclax, acute myeloid leukemia, chronic lymphocytic leukemia, cyclophosphamide, neuroblastoma, p53, p53-wild-type, MYCN-amplified neuroblastomas, patient, patients, pediatric cancer, prosurvival protein BCL-2, topotecan, tumor, venetoclax
Author NameAffiliation
Kateryna KrytskaDivision of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia
Kateryna KrytskaUniversity of Pennsylvania Perelman School of Medicine
Mikhail G DozmorovVirginia Commonwealth University
Cyril H BenesCenter for Cancer Research, Massachusetts General Hospital, Harvard Medical School
Yael P MosseDivision of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia
Yael P MosseUniversity of Pennsylvania Perelman School of Medicine
  • 1 - 6

Datasets

Release 1.2